“GROUNDBREAKING SCIENCE. BREAKTHROUGH MEDICINE.” 

The new healthcare venture, BOCOSV-ReGen Med, debuts with acquisition of human neural stem cell technology (hNSC), a purified, expanded and banked stem cell product. Preclinical and early clinical data provided the rationale for BOCO’s acquisition of the technology.
The key attributes of neural stem cells – such as self-renewal to provide a continuous
reservoir of factor-producing cells, global CNS migratory properties, and their innate ability to form new normal neurons, astrocytes or oligodendrocytes formed the basis for the initiation of translational studies in select human CNS disorders. The properties of our human neural stem cell, hNSC, distinguish them from the many other cell based
approaches currently being promoted in regenerative medicine and position them as
attractive novel therapeutics for treating the plethora of neurodegenerative conditions.
The human neural stem cells have been tested in four different indications into the brain, spinal cord or eye. To date, an excellent safety profile has been observed with no evidence of abnormal growth; the longest time point is 9 years post-transplant of the cells. Moreover, emerging signs of clinical efficacy compels BOCOSV-ReGen Med to further test the ability of hNSC’s to protect the retina of people suffering from the neurodegenerative condition, dry age-related macular degeneration.

Overview of the hNSC isolation, expansion and banking, and Final Product.